SIDE-BY-SIDE EVIDENCE
Compare evidence.
Keep the context.
Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.
Choose profilesSIDE-BY-SIDE EVIDENCE VIEW
Compare selected profiles
| Molecule |  hGH Fragment 176-191 | AOD-9604 | Somatropin |
|---|---|---|---|
| Research Topic | Growth Hormone Biology | Growth Hormone Biology | Growth Hormone Biology |
| Pharmacology | Growth-hormone C-terminal peptide fragment | Synthetic 16-amino-acid C-terminal human growth hormone fragment analogue | Recombinant 191-amino-acid human growth hormone and GH-receptor agonist |
| PrimeCore Class | Class CExperimental / limited evidence | Class CExperimental / limited evidence | Class AApproved in a bounded context |
| Evidence Grade | Grade EPreclinical evidence | Grade DLimited / observational evidence | Grade AStrong regulatory + clinical evidence |
| Evidence boundary | hGH Fragment 176-191 is not full-length somatropin and should not be equated with AOD-9604 without structural verification. A rat study reported glucose/insulin effects of several C-terminal fragments. It does not establish human fat loss or freedom from metabolic risk. | A synthetic 16-amino-acid human-growth-hormone fragment analogue whose pivotal obesity study did not meet its weight-loss endpoint; it is not FDA-approved and remains prohibited in sport. | Recombinant human growth hormone with the 191-amino-acid sequence of pituitary GH. Approved medicines have diagnosis-specific growth or replacement indications; an online 'HGH 191AA' label does not establish identity, quality, approval, anti-aging benefit or bodybuilding efficacy. |
| Unknowns | Insufficient data in the current dataset | Insufficient data in the current dataset | Insufficient data in the current dataset |
| Limitations | English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language)
| Insufficient data in the current dataset | Insufficient data in the current dataset |
| Sources |
|
| |
| Read more | Read English overview | Read English overview | Read English overview |
This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.
Choose another comparisonContinue reading
Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.
10 questions before drawing conclusions